Boston Immune Technologies & Therapeutics

0 followers


BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.

Employees

1-10

Links


Org chart

Collapse
David Brooks
Chief Medical Officer
Bruce Weaver
VP of Manufacturing
Elena Ende
Finance Director
Steve Andress
Director of Legal

Board & advisors

Lusong Luo
Board Member

Teams

This company has no teams yet